Top

Strahlentherapie und Onkologie

Published in:

01-03-2012 | Original article

High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer

Authors: O.P. Erpolat, P.U. Gocun, M. Akmansu, E. Karakus, G. Akyol

Published in: Strahlentherapie und Onkologie | Issue 3/2012

Abstract

Background and purpose

Survivin is one of the apoptosis inhibitor proteins. Together with Aurora B, it also plays a role in regulating several aspects of mitosis. High expression of these markers is correlated with malignant behavior of various cancers and resistance to therapy. Our aim was to evaluate the prognostic role of these markers in head and neck cancers.

Patients and methods

We evaluated the expression of Aurora B and survivin in tissue specimens of 58 patients with head and neck squamous cell carcinoma using immunohistochemistry.

Results

Patients who showed high expression of cytoplasmic and nuclear survivin and Aurora B had significantly shorter overall survival (p = 0.036, p < 0.000, p = 0.032, respectively). In multivariate analysis, high expression of nuclear survivin was the only independent negative prognostic factor (p = 0.024). Moreover, it was found that high co-expression of nuclear survivin and Aurora B had a negative effect on survival in univariate (p < 0.000) and multivariate (p < 0.000) analyses.

Conclusion

The negative prognostic values of high expression of Aurora B and high co-expression of nuclear survivin and Aurora B on survival were shown. These findings suggest that co-expression of nuclear survivin and Aurora B can be useful diagnostic markers and therapeutic targets for head and neck squamous cell carcinoma. However, further studies with a larger number of patients in a more homogeneous disease group are needed to confirm the conclusion.

Brizel DM (2008) The role of combined radiotherapy and chemotherapy in the management of locally advanced squamous carcinoma of the head and neck. In: Halperin EC, Perez CA, Brady LW (eds) Principles and practice of radiation oncology. 5th edn. Lippincott Williams and Wilkins, Philadelphia, PA, pp 807

Rades D, Seibold ND, Gebhard MP et al (2011) Prognostic factors (including HPV status) for irradiation of locally advanced squamous cell carcinoma of the head and neck (SCCHN). Strahlenther Onkol 187:626–632PubMedCrossRef

Farrag A, Voordeckers M, Tournel K et al (2010) Pattern of failure after helical tomotherapy in head and neck cancer. Strahlenther Onkol 186:511–516PubMedCrossRef

Jacob V, Bayer W, Astner ST et al (2010) A planning comparison of dynamic IMRT for different collimator leaf thickness with helical tomotherapy and RapidArc for prostate and head and neck tumors. Strahlenter Onkol 186:502–510CrossRef

Eder-Czembirek C, Erovic BM, Czembirek C et al (2010) Betulinic acid a radiosensitizer in head and neck squamous cell carcinoma cell lines. Strahlenther Onkol 186:143–148PubMedCrossRef

Reed JC (2002) Apoptosis based therapies. Nat Rev Drug Discov 1:111–121PubMedCrossRef

LaCasse EC, Baird S, Korneluk RG et al (1998) The inhibitor of apoptosis and their emerging role in cancer. Oncogene 17:3247–3259PubMedCrossRef

Dahi T, Okada K, Xia F (2004) An IAP-IAP complex inhibits apoptosis. J Biol Chem 279:34087–34090CrossRef

Chiou SK, Jones MK, Tarnawski AS (203) Survivin–an apoptosis protein: its biological roles and implications for cancer and beyond. Med Sci Monit 9:125–129

10.

Li F, Ling X (2006) Survivin study: an update of ‘what is the next wave?’ J Cell Physiol 208:476–486

11.

Altieri DC (2006) The case for Survivin as a regulator of microtubule dynamics and cell death decisions. Curr Opin Cell Biol 18:609–615PubMedCrossRef

12.

Capalbo G, Rödel C, Stauber RH et al (2007) The role of survivin for radiation therapy. Strahlenther Onkol 183:593–599PubMedCrossRef

13.

Altieri DC (2003) Survivin, versatile modulation of cell division and apoptosis in cancer. Oncogene 22:8581–8589PubMedCrossRef

14.

Adams RR, Carmena M, Earnshaw WC (2001) Chromosomal passengers and the (aurora) ABCs of mitosis. Trends Cell Biol 11:49–54PubMedCrossRef

15.

Bolton MA, Lan W, Powers SE et al (2002) Aurora B kinase exists in a complex with survivin and INCENP and its kinase activity is stimulated by survivin binding and phosphorylation. Mol Biol Cell 13:3064–3077PubMedCrossRef

16.

Cheung CH, Coumar MS, Hsieh HP (2009) Aurora kinase inhibitors in preclinical and clinical testing. Expert Opin Investig Drugs 18:379–398PubMedCrossRef

17.

Altieri DC (2003) Validating survivin as a cancer therapeutic target. Nat Rev Cancer 3:46–54PubMedCrossRef

18.

Rödel F, Hoffmann J, Grabenbauer GG et al (2002) High survivin expression is associated with reduced apoptosis in rectal cancer and may predict disease free survival after preoperative radiochemotherapy and surgical resection. Strahlenther Onkol 178:426–435PubMedCrossRef

19.

Adams RR, Eckley DM, Vagnarelli P et al (2001) Human INCENP colocalizes with the Aurora-B/AIRK2 kinase on chromosomes and is overexpressed in tumor cells. Chromosoma 110:65–74PubMedCrossRef

20.

Mesri M, Wall NR, Li J Kim RW et al (2001) Cancer gene therapy using a survivin mutant adenovirus. J Clin Invest 108:981–990PubMed

21.

Keen M, Taylor S (2004) Aurora-kinase inhibitors as anti-cancer agents. Nat Rev Cancer 4:927–936PubMedCrossRef

22.

Lin ZZ, Hsu HC, Hsu CH et al (2009) The aurora kinase inhibitor VE-465 has anticancer effects in preclinical studies of human hepatocellular carcinoma. J Hepatol 50:18–24CrossRef

23.

Li F, Yang J, Ramnath N et al (2005) Nuclear or cytoplasmic survivin: what is the significance? Int J Cancer 114:509–512PubMedCrossRef

24.

Kurai M, Shiozawa T, Shih HC et al (2005) Expression of Aurora kinases A and B in normal, hyperplastic, and malignant human endometrium: Aurora-B as a predictor for poor prognosis in endometrial carcinoma. Hum Pathol 36:1281–1288PubMedCrossRef

25.

Lopez-Kios F, Chuai S et al (2006) Global gene expression profiling of pleural mesotheliomas: over-expression of aurora kinases and p16/CDKN2A deletion as prognostic factors and critical evaluation of micro-array based prognostic prediction. Cancer Res 66:2970–2979CrossRef

26.

Dong Y, Sui L, Watanabe Y et al (2002) Survivin expression in laryngeal squamous cell carcinoma and its prognostic implications. Anticancer Res 22:2377–2383PubMed

27.

Lo Muzio L, Pannone G, Staibano S et al (2003) Survivin expression in oral squamous cell carcinoma. Br J Cancer 89:2244–2248CrossRef

28.

Lo Muzio L, Farina A, Rubini C et al (2005) Survivin as prognostic factor in squamous cell carcinoma of the oral cavity. Cancer Lett 225:27–33CrossRef

29.

Qi G, Ogawa I, Kudo Y et al (2007) Aurora-B expression and its correlation with cell proliferation and metastasis in oral cancer. Virchows Arch 450:297–302PubMedCrossRef

30.

Qi G, Kudo Y, Ando T et al (2010) Nuclear Survivin expression is correlated with malignant behaviors of head and neck cancer together with Aurora-B. Oral Oncol 46:263–270PubMedCrossRef

31.

Stauber RH, Mann W, Knauer SK (2007) Nuclear and cytoplasmic survivin: molecular mechanism, prognostic and therapeutic potential. Cancer Res 67:5999–6002PubMedCrossRef

32.

Altieri DC (2008) Survivin, cancer networks and pathway-directed drug discovery. Nat Rev Cancer 8:61–70PubMedCrossRef

33.

Rödel F, Reichert S, Sprenger T et al (2011) The role of survivin for radiation oncology: moving beyond apoptosis inhibition. Curr Med Chem 18:191–199PubMedCrossRef

34.

Kelly AE, Ghenoiu C, Xue JZ et al (2010) Survivin reads phosphorylated histone H3 threonine 3 to activate the mitotic kinase Aurora B. Science 330:235–239PubMedCrossRef

35.

Ota T, Suto S, Katayama H et al (2002) Increased mitotic phosphorylation of histone H3 attributable to AIM-1/Aurora-B overexpression contributes to chromosome number instability. Cancer Res 62:5168–5177PubMed

36.

Ambrosini G, Adida C, Altieri DC (1997) A novel anti-apoptosis gene, survivin, expressed in cancer and lymphoma. Nat Med 3:917–921PubMedCrossRef

37.

Preuss SF, Weinell A, Molitor M et al (2008) Nuclear survivin expression is associated with HPV independent carcinogenesis and is an indicator of poor prognosis in oropharyngeal cancer. Br J Cancer 98:627–632PubMedCrossRef

38.

Katayama H, Ota T, Jisaki F et al (1999) Mitotic kinase expression and colorectal cancer progression. J Natl Cancer Inst 91:1160–1162PubMedCrossRef

39.

Freier K, Pungs S, Sticht C et al (2007) High survivin expression is associated with favorable outcome in advanced primary oral squamous cell carcinoma after radiation therapy. Int J Cancer 4:942–946CrossRef

40.

Lin CY, Hung HC, Kuo RC et al (2005) Survivin expression predicts poorer prognosis in patients with areca quid chewing-related oral squamous cell carcinoma in Taiwan. Oral Oncol 41:645–654PubMedCrossRef

41.

Grabowski P, Kuhnel T, Muhr-Wilkenshoff F et al (2003) Prognostic value of nuclear survivin expression in esophageal squamous cell carcinoma. Br J Cancer 88:115–119PubMedCrossRef

42.

Engels K, Knauer SK, Metzler D et al (2007) Dynamic intracellular survivin in oral squamous cell carcinoma: underlying molecular mechanism and potential as an early prognostic marker. J Pathol 211:532–540PubMedCrossRef

43.

Tatsuka M, Katayama H, Ota T et al (1998) Multinuclearity and increased ploidy caused by overexpression of the aurora- and Ipl1-like midbody-associated protein mitotic kinase in human cancer cells. Cancer Res 58:4811–4816PubMed

44.

Jung JE, Kim TK, Lee JS et al (2005) Survivin inhibits anti-growth effect of p53 activated by aurora B. Biochem Biophys Res Commun 336:1164–1167PubMedCrossRef

Title: High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer
Authors: O.P. Erpolat
P.U. Gocun
M. Akmansu
E. Karakus
G. Akyol
Publication date: 01-03-2012
Publisher: Springer-Verlag
Published in: Strahlentherapie und Onkologie / Issue 3/2012
Print ISSN: 0179-7158
Electronic ISSN: 1439-099X
DOI: https://doi.org/10.1007/s00066-011-0042-7

At a glance: The STEP trials

Springer Medicine

High expression of nuclear survivin and Aurora B predicts poor overall survival in patients with head and neck squamous cell cancer

Abstract

Background and purpose

Patients and methods

Results

Conclusion

At a glance: The STEP trials

Springer Medicine

Abstract

Background and purpose

Patients and methods

Results

Conclusion

Please log in to get access to this content

Other articles of this Issue 3/2012

RapidArc combined with the active breathing coordinator provides an effective and accurate approach for the radiotherapy of hepatocellular carcinoma

Radiation-induced changes in breathing frequency and lung histology of C57BL/6J mice are time- and dose-dependent

Evidenz für den Einsatz moderner Bestrahlungstechniken beim nicht-kleinzelligen Bronchialkarzinom: unnötig, ungenügend, ausreichend oder zu spät?

Limited disease of extra-pulmonary small cell carcinoma

Radiation-induced cranial neuropathy in patients with nasopharyngeal carcinoma

Subjektive Einschätzung der Stimmqualität nach operativer oder strahlentherapeutischer Behandlung eines glottischen Kehlkopfkarzinoms im Stadium T1